 total androgen ablat european experi eortc GU group zoladex time progress subject object first progress orchiectomi differ surviv death caus malign diseas delay appear progress surviv fact durat surviv progress zoladex evid surviv benefit zoladex qualiti control data acknowledg problem respons patient advanc prostat cancer review bone scan committe data tabl data reflect heterogen studi patient popul tabl pain respons week mani item committe respons criteria qualiti life trial similar problem work patienc firm answer clinic problem effort combin result trial knowledg treat histori prostat cancer net treatment benefit subset patient treatment patient anonym mass case advanc prostat cancer reward continu collabor studi group